Healthcare Services

Neuropathic Pain Market Analysis Reflecting Expansion Trends And Industry Performance

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Neuropathic Pain Market By 2030?

The neuropathic pain market has seen robust expansion in recent years. It is forecast to grow from $5.78 billion in 2025 to $6.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This past growth is attributable to an increase in diabetes prevalence, the early embrace of antidepressants and anticonvulsants, enhanced understanding of neuropathic pain conditions, the creation of opioid-based treatments, and the initial application of imaging for diagnosis.

The neuropathic pain market is anticipated to experience robust growth in the coming years. It is projected to expand to $8.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This expansion throughout the forecast period stems from a rising inclination towards non-opioid treatments, an increasing need for individualized pain management, the broader utilization of complementary therapies, enhanced investment in diagnostic innovations, and the development of advanced multimodal treatment solutions. Prominent trends for the forecast duration encompass the growing acceptance of multimodal therapy approaches, an escalating demand for non-opioid pain management, the increasing incorporation of physical and psychological therapies, the widening scope of early diagnosis through imaging techniques, and a heightened focus on diabetic neuropathy treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

Which Core Factors Are Supporting The Expansion Of The Neuropathic Pain Market?

The expansion of the neuropathic pain market is anticipated to be driven by the increasing occurrence of chronic pain. This condition, defined as persistent discomfort extending for three months or longer, affects a considerable segment of the population, profoundly diminishing their quality of life. The surge in chronic pain cases stems from contributing factors such as an aging demographic, nerve damage, and long-term health issues including diabetes. Neuropathic pain treatments contribute to public health by addressing nerve dysfunction, alleviating symptoms, and enhancing patients’ ability to perform daily activities. To illustrate, data released by the Centers for Disease Control and Prevention (CDC), a US-based nation’s health protection agency, in November 2024, indicated that in 2023, 24.3% of adult populations experienced chronic pain, with 8.5% suffering from high-impact chronic pain. This figure equates to 34.9% among those with chronic pain, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older exhibiting particularly elevated rates. Consequently, the increasing prevalence of chronic pain is serving as a catalyst for the neuropathic pain market.

What Are The Core Segment Classifications In The Neuropathic Pain Market?

The neuropathic pain market covered in this report is segmented –

1) By Treatment: Medications, Multimodal Therapy

2) By Diagnosis: Imaging, Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications

4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

Which Trends Are Expected To Shape The Neuropathic Pain Market?

Major companies operating in the neuromyelitis optica spectrum disorder market are actively pursuing the creation of innovative products, such as long-acting complement inhibitors, to elevate treatment effectiveness and enhance patient well-being. These long-acting complement inhibitors function by inhibiting the complement system for an extended duration, thereby curbing inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD). They contribute to reducing occurrences of relapses and aiding in sustained disease management. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical firm, and AstraZeneca, a UK-based pharmaceutical company, secured regulatory clearance for ULTOMIRIS (ravulizumab-cwvz) for treating adults diagnosed with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This approval establishes Ultomiris as the first and only long-acting C5 complement inhibitor accessible for NMOSD treatment. This authorization was substantiated by findings from the Phase III CHAMPION-NMOSD trial, where Ultomiris exhibited a 98.6% decrease in relapse risk over 73 weeks when compared to a placebo. Participants in the trial did not encounter any relapses, and no novel safety issues emerged.

Who Are The Companies Shaping The Neuropathic Pain Market Landscape?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd

Access The Complete Neuropathic Pain Market Report:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Which Region Holds The Largest Share In The Neuropathic Pain Market?

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neuropathic Pain Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company

Optic Atrophy Management Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Peripheral Neuropathy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Retinal Disorder Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795